Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
854 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06093672 | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera(GIV-IN-PV) | recruiting | Phase 3 | 220 | ItalfarmacoINDUSTRY | 16 | Mar 25, 2026 | clinicaltrials |
| NCT06646861 | Head and Neck Cancer Rehabilitation: The CaRe Feasibility Study(CaRe) | completed | N/A | 22 | University of Dublin, Trinity CollegeOTHER | 1 | Mar 25, 2026 |
| clinicaltrials |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | recruiting | Phase 3 | 1,000 | European Myeloma Network B.V.NETWORK | 18 | Mar 25, 2026 | clinicaltrials |
| NCT04003636 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)(KEYNOTE-966) | completed | Phase 3 | 1,069 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Mar 24, 2026 | clinicaltrials |
| NCT04095364 | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 450 | NRG OncologyOTHER | 6 | Mar 24, 2026 | clinicaltrials |
| NCT06726265 | Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | active not recruiting | Phase 3 | 756 | Immutep S.A.S.INDUSTRY | 27 | Mar 18, 2026 | clinicaltrials |
| NCT07477938 | A Single-Arm Interventional Trial of Pepper- Robot Delivered Cancer Education for Adults With Intellectual Disability(Pep-SMARTID) | not yet recruiting | N/A | 25 | National University of Ireland, Galway, IrelandOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT02655016 | A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | active not recruiting | Phase 3 | 733 | Tesaro, Inc.INDUSTRY | 14 | Mar 10, 2026 | clinicaltrials |
| NCT03142334 | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | completed | Phase 3 | 994 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 10, 2026 | clinicaltrials |
| NCT05116189 | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). | active not recruiting | Phase 3 | 643 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Mar 9, 2026 | clinicaltrials |
| NCT04262466 | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | active not recruiting | Phase 1 / Phase 2 | 410 | Immunocore LtdINDUSTRY | 17 | Mar 6, 2026 | clinicaltrials |
| NCT07455422 | A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer(Endeavor-2) | not yet recruiting | N/A | 266 | University Hospital, AntwerpOTHER | 7 | Mar 6, 2026 | clinicaltrials |
| NCT04222972 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)(AcceleRET-Lung) | terminated | Phase 3 | 223 | Hoffmann-La RocheINDUSTRY | 22 | Mar 5, 2026 | clinicaltrials |
| NCT05035173 | The LYSA (Linking You to Support and Advice) Trial(LYSA) | completed | N/A | 200 | University College CorkOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05866757 | Discontinuation Study | recruiting | N/A | 70 | University College CorkOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06472856 | Vasomotor Symptom Alleviation Through Acupuncture in Patients With Prostate Cancer(VASA Pro) | completed | N/A | 12 | University College CorkOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06546631 | Investigating Mechanistic Predictors of Interpatient Variability and Temozolomide (TMZ) Induced Haematological Toxicity for Glioma Patients(Improve TMZ) | recruiting | — | 55 | University College CorkOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06709651 | Microbiome Immunotherapy Neoadjuvant Assessment(MINA) | recruiting | — | 30 | University College CorkOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07443579 | Optimal Mammography View Sequencing in Women With a History of Breast Cancer Undergoing Surveillance Mammography(MammoView) | recruiting | N/A | 400 | Royal College of Surgeons, IrelandOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03675737 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | completed | Phase 3 | 1,579 | Merck Sharp & Dohme LLCINDUSTRY | 33 | Feb 27, 2026 | clinicaltrials |
| NCT07411105 | Cognition in Older Adults With Cancer Receiving Systemic Anti-Cancer Therapy(CORreCT) | active not recruiting | — | 30 | Our Lady's Hospice and Care ServicesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05896566 | A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer(PREcoopERA) | completed | Phase 2 | 231 | ETOP IBCSG Partners FoundationNETWORK | 6 | Feb 24, 2026 | clinicaltrials |
| NCT06523374 | A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer(Endeavor-1) | recruiting | N/A | 50 | University Hospital, AntwerpOTHER | 6 | Feb 24, 2026 | clinicaltrials |
| NCT02811861 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma(CLEAR) | active not recruiting | Phase 3 | 1,069 | Eisai Inc.INDUSTRY | 20 | Feb 23, 2026 | clinicaltrials |
| NCT05171049 | A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE(ASTER) | terminated | Phase 3 | 1,150 | Anthos Therapeutics, Inc.INDUSTRY | 21 | Feb 23, 2026 | clinicaltrials |
| NCT07426835 | The PHARO Trial: The Incidence of Para-conduit Hernia With Closure of Hiatus Versus the Standard Approach in Robotic Oesophagectomy - A Randomised Controlled Pilot Trial(PHARO) | recruiting | N/A | 40 | Royal College of Surgeons, IrelandOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07426848 | OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients(OTSMILE) | recruiting | N/A | 96 | Royal College of Surgeons, IrelandOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07426861 | Pre-Operative Nurse-Led Education With Direct Physiotherapy Referral to Reduce Post-Prostatectomy Incontinence(PRO-ACT) | recruiting | N/A | 80 | Royal College of Surgeons, IrelandOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07426874 | eHealth Support Tool to Improve Quality of Life in Head and Neck Cancer Survivors | active not recruiting | N/A | 30 | Royal College of Surgeons, IrelandOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04221945 | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) | completed | Phase 3 | 1,060 | Merck Sharp & Dohme LLCINDUSTRY | 30 | Feb 20, 2026 | clinicaltrials |
| NCT05527184 | First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | active not recruiting | Phase 1 | 256 | AbbVieINDUSTRY | 10 | Feb 20, 2026 | clinicaltrials |
| NCT07422727 | Impact of Cooling Mats on Vasomotor Symptoms in Patients Receiving Endocrine Therapy(COOLVAS) | enrolling by invitation | N/A | 40 | Sligo General HospitalOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07425002 | Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM)(PRISM) | recruiting | N/A | 1,600 | Cancer Trials IrelandNETWORK | 1 | Feb 20, 2026 | clinicaltrials |
| NCT02308085 | Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer(POSITIVE) | active not recruiting | N/A | 518 | ETOP IBCSG Partners FoundationNETWORK | 22 | Feb 9, 2026 | clinicaltrials |
| NCT03713593 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | completed | Phase 3 | 794 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Feb 5, 2026 | clinicaltrials |
| NCT03884101 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)(LEAP-001) | completed | Phase 3 | 842 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Feb 2, 2026 | clinicaltrials |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(BRUIN CLL-322) | active not recruiting | Phase 3 | 600 | Loxo Oncology, Inc.INDUSTRY | 23 | Jan 29, 2026 | clinicaltrials |
| NCT03367702 | Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer | active not recruiting | Phase 3 | 692 | NRG OncologyOTHER | 6 | Jan 15, 2026 | clinicaltrials |
| NCT05041257 | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers(PICCOLO) | completed | Phase 2 | 79 | AbbVieINDUSTRY | 7 | Jan 9, 2026 | clinicaltrials |
| NCT05740566 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer(DeLLphi-304) | active not recruiting | Phase 3 | 509 | AmgenINDUSTRY | 31 | Jan 5, 2026 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT03869892 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.(SOLSTICE) | active not recruiting | Phase 3 | 856 | Institut de Recherches Internationales ServierOTHER | 25 | Dec 22, 2025 | clinicaltrials |
| NCT01840293 | Breast Cancer Proteomics and Molecular Heterogeneity | recruiting | — | 1,780 | Cancer Trials IrelandNETWORK | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02050750 | TAILORx Tissue Bank | active not recruiting | — | 600 | Cancer Trials IrelandNETWORK | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03215706 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC(CheckMate 9LA) | completed | Phase 3 | 719 | Bristol-Myers SquibbINDUSTRY | 19 | Dec 17, 2025 | clinicaltrials |
| NCT06211036 | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab(DeLLphi-305) | active not recruiting | Phase 3 | 563 | AmgenINDUSTRY | 29 | Dec 17, 2025 | clinicaltrials |
| NCT04270409 | Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma | active not recruiting | Phase 3 | 337 | SanofiINDUSTRY | 24 | Dec 12, 2025 | clinicaltrials |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy(COSMIC-312) | active not recruiting | Phase 3 | 837 | ExelixisINDUSTRY | 34 | Dec 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials